CoChat
Sign Up
Cited by 155Attention Deficit Hyperactivity DisorderPharmacovigilance and Adverse Drug ReactionsSchizophrenia research and treatment

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Hallucinations and Other Psychotic Symptoms Associated With the Use of Attention-Deficit/Hyperactivity Disorder Drugs in Children

Mosholder, Andrew D., Gelperin, Kate, Hammad, Tarek A., Phelan, Kathleen, Johann-Liang, Rosemary·2009·Pediatrics
DOI 10.1542/peds.2008-0185
Open this paper in CoChat — free account

Abstract

Objectives To gain a better understanding of the capacity of psychostimulant medications to induce adverse psychiatric reactions and determine the frequency of such reactions, we analyzed postmarketing surveillance data and clinical trial data for drugs, either approved or under development, for the treatment of attention-deficit/hyperactivity disorder. Methods The US Food and Drug Administration requested manufacturers of drugs approved for attention-deficit/hyperactivity disorder or with active clinical development programs for that indication to search their electronic clinical trial databases for cases of psychosis or mania using prespecified search terms. The manufacturers supplied descriptions of clinical trials, numbers of patients exposed to study drug, and duration of exposure to permit calculations of incidence rates. Independently, cases of psychosis or mania in children and adults for drugs used to treat attention-deficit/hyperactivity disorder from the Food and Drug Administration Adverse Event Reporting System safety database were analyzed. Manufacturers were asked to conduct similar analyses of their postmarketing surveillance databases. Results We analyzed data from 49 randomized, controlled clinical trials in the pediatric development programs for these products. A total of 11 psychosis/mania adverse events occurred during 743 person-years of double-blind treatment with these drugs, and no comparable adverse events occurred in a total of 420 person-years of p…

Overview

Integrity signals

Registry

Crossref · 10.1542/peds.2008-0185

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 15 references

Cited by

Sorted by citations

Items 101–155 of 155

Related

See all

Metadata

Authors
Mosholder, A. D., Gelperin, K., Hammad, T. A., Phelan, K., & Johann-Liang, R.
Affiliations
  • United States Food and Drug Administration (US)
  • Health Resources and Services Administration, Department of Health and Human Services, Rockville, Maryland
Corresponding author
Gelperin, Kate
ORCID
Venue
Pediatrics
Publisher
American Academy of Pediatrics (AAP)
Published
2009-02-01
Volume
123
Issue
2
Pages
611-616
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
DOI
10.1542/peds.2008-0185
OpenAlex
W2092853583
Cited by
155
References
15
Citations by year
2026: 3 · 2025: 5 · 2024: 10 · 2023: 4 · 2022: 8 · 2021: 6 · 2020: 15 · 2019: 18 · 2018: 7 · 2017: 10 · 2016: 7 · 2015: 12 · 2014: 8 · 2013: 6 · 2012: 8
FWCI
7.38
Type
journal article
Language
en
Open access
closed
Locations
  • PEDIATRICS (publishedVersion)
  • PubMed (publishedVersion)
Funders
Eli Lilly and Company
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
attention deficit hyperactivity disorder, psychostimulants, psychosis, mania, hallucinations, adverse drug reactions, drug safety in children, post-marketing surveillance, FDA Adverse Event Reporting System
MeSH terms
Attention Deficit Disorder with Hyperactivity, Child, Female, Hallucinations, Humans, Male, Psychoses, Substance-Induced, Adverse Drug Reaction Reporting Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review